Suppr超能文献

脂肪肝指数及其与10年动脉粥样硬化性心血管疾病风险的关联:来自中国一项基于人群的横断面研究的见解

Fatty Liver Index and Its Association with 10-Year Atherosclerotic Cardiovascular Disease Risk: Insights from a Population-Based Cross-Sectional Study in China.

作者信息

Zhou Jing, Fan Jing, Zhang Xiaoyun, You Lili, Lin Diaozhu, Huang Chulin, Li Feng, Sun Kan

机构信息

Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiang West Road, Guangzhou 510120, China.

出版信息

Metabolites. 2023 Jul 14;13(7):850. doi: 10.3390/metabo13070850.

Abstract

This cross-sectional study aimed to investigate the association between non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD), a global public health concern. A total of 9044 out of 10,104 adults from Guangzhou, China, were included in the analysis. We utilized the fatty liver index (FLI), a noninvasive indicator of NAFLD, and the pooled cohort equations (PCE) based on the 2013 ACC/AHA Guideline, the China-PAR model, and the Framingham Risk Score to assess the 10-year ASCVD risk. The results demonstrated a significant association between FLI and 10-year ASCVD risk ( < 0.001). Adjusted for age, individuals with high FLI (≥60) had an odds ratio of 3.91 (95% CI 2.52-6.08) compared to those with low FLI (<30). These findings persisted after adjusting for metabolic indicators. Notably, this association was consistently observed across all three risk prediction models: the PCE model, the China-PAR model, and the Framingham Risk Score. In conclusion, our study provides evidence supporting FLI as a reliable indicator of increased 10-year ASCVD risk in Chinese NAFLD patients. FLI serves as a valuable marker for early detection of ASCVD, highlighting its potential in clinical practice for risk assessment and prevention strategies.

摘要

这项横断面研究旨在调查非酒精性脂肪性肝病(NAFLD)与动脉粥样硬化性心血管疾病(ASCVD)之间的关联,这是一个全球公共卫生问题。在中国广州的10104名成年人中,共有9044人纳入分析。我们使用了非酒精性脂肪性肝病的无创指标——脂肪肝指数(FLI),以及基于2013年美国心脏病学会/美国心脏协会指南、中国-PAR模型和弗明汉风险评分的合并队列方程(PCE)来评估10年ASCVD风险。结果显示FLI与10年ASCVD风险之间存在显著关联(<0.001)。在调整年龄后,高FLI(≥60)的个体与低FLI(<30)的个体相比,优势比为3.91(95%CI 2.52-6.08)。在调整代谢指标后,这些发现依然存在。值得注意的是,在所有三个风险预测模型中均一致观察到这种关联:PCE模型、中国-PAR模型和弗明汉风险评分。总之,我们的研究提供了证据,支持FLI作为中国非酒精性脂肪性肝病患者10年ASCVD风险增加的可靠指标。FLI是早期检测ASCVD的一个有价值的标志物,突出了其在临床实践中进行风险评估和预防策略的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffbd/10385028/6af1df04d728/metabolites-13-00850-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验